Department of Medicine

Acute Hematologic Malignancies Symposium


2023 Symposium


The 2023 Acute Hematologic Malignancies Symposium will be held Saturday, March 25, 2023.

This symposium will bring together recognized national and international speakers to address recent advances in the diagnosis of myelodysplastic syndrome (MDS) and measurable residual disease [MRD] directed acute myelogenous leukemia (AML) therapy. During our symposium, we will emphasize the need for physicians to combine up-to-date knowledge and technology to efficiently identify “actionable targets” for the treatment of AML and MDS patients. Additionally, we expect to gain insight into promising scientific data that would inform therapy efficacy based on AML MRD evaluation. The symposium will provide important novel development in MDS and AML pathogenesis leading to unique opportunities for clinical trial design ideas.

Key topics include:

  • Molecular Basis of Clonal Hematopoiesis
  • Myelodysplasia and Chronic Myelodysplasis and Chronic Myelomonocytic Leukemia
  • Acute Myelogenous Leukemia
  • Myeloproliferative Neoplasms

For further information on other Baylor College CPD activities or free online CME activities, email

View the brochure, flyer and agenda.

Register now

2021 Symposium Highlights


The Third Annual Hematologic Malignancy Symposium was held March 13, 2021. View the following for information on the past event:

Symposium Overview

During our third symposium, we brought together national and international acclaimed leukemia scientists to discuss recent advances in clonal hematopoiesis, low/high risk myelodysplastic syndrome, targeted AML therapy with emphasis in novel HMA plus BCL-2 inhibitor combination, advances in P53 myeloid malignancies therapies.

During our 2021 symposium, we incorporated state-of- the-art lectures on post induction HMA treatment, mechanisms of FLT3 inhibition resistance and how to manage elderly AML patients. A highly interactive update on HMA plus BCL-2 inhibitor therapy was followed by a panel discussion on post induction AML maintenance.

Additionally, the symposium provided important novel development in MDS and AML pathogenesis leading to unique opportunity for clinical trial design ideas.